Effects of 1-methyltryptophan stereoisomers on IDO2 enzyme activity and IDO2-mediated arrest of human T cell proliferation

Cancer Immunology, Immunotherapy

Volumn 61, Issue 11, 2012, Pages 2013-2020

  Qian, Feng ^a   Liao, Jianqun ^a   Villella, Jeannine ^b   Edwards, Robert ^c   Kalinski, Pawel ^c   Lele, Shashikant ^a   Shrikant, Protul ^a   Odunsi, Kunle ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Human; IDO2; L 1MT; T cell

Indexed keywords

1 METHYLTRYPTOPHAN; DEXTRO 1 METHYLTRYPTOPHAN; DOXORUBICIN; ENZYME INHIBITOR; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 1; INDOLEAMINE 2,3 DIOXYGENASE 2; KYNURENINE; TRYPTOPHAN; UNCLASSIFIED DRUG;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STRAIN HEK293; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEGRADATION; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENINE; LYMPHOCYTE ACTIVATION; STEREOISOMERISM; TRYPTOPHAN;

EID: 84870990555     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1265-x     Document Type: Article

References (24)

1. Mellor AL, Munn DH (2008) Creating immune privilege: Active local suppression that benefits friends, but protects foes. Nat Rev 8(1):74-80
2. Grohmann U, Fallarino F, Puccetti P (2003) Tolerance, DCs and tryptophan: Much ado about IDO. Trends Immunol 24(5):242-248
3. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9(10): 1269-1274
4. Mellor AL, Munn DH (2004) IDO expression by dendritic cells: Tolerance and tryptophan catabolism. Nat Rev Immunol 4(10):762-774
5. Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, Messina JL, Chandler P, Koni PA, Mellor AL (2004) Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 114(2):280-290
6. Ino K, Yoshida N, Kajiyama H, Shibata K, Yamamoto E, Kidokoro K, Takahashi N, Terauchi M, Nawa A, Nomura S, Nagasaka T, Takikawa O, Kikkawa F (2006) Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer 95(11):1555-1561
7. Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, Werner ER, Werner-Felmayer G, Weiss HG, Gobel G, Margreiter R, Konigsrainer A, Fuchs D, Amberger A (2006) Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: Effect on tumor-infiltrating T cells. Clin Cancer Res 12(4):1144-1151
8. Okamoto A, Nikaido T, Ochiai K, Takakura S, Saito M, Aoki Y, Ishii N, Yanaihara N, Yamada K, Takikawa O, Kawaguchi R, Isonishi S, Tanaka T, Urashima M (2005) Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 11(16):6030-6039
9. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, Odunsi K (2005) Intraepithelial CD8? tumor-infiltrating lymphocytes and a high CD8?/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Nat Acad Sci USA 102(51): 18538-18543
10. Munn DH (2006) Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr Opin Immunol 18(2): 220-225
11. Qian F, Villella J, Wallace PK, Mhawech-Fauceglia P, Tario JD Jr, Andrews C, Matsuzaki J, Valmori D, Ayyoub M, Frederick PJ, Beck A, Liao J, Cheney R, Moysich K, Lele S, Shrikant P, Old LJ, Odunsi K (2009) Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3- dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer. Cancer Res 69(13):5498-5504
12. Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC (2007) Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyltryptophan. Cancer Res 67(15):7082-7087
13. Ball HJ, Yuasa HJ, Austin CJ, Weiser S, Hunt NH (2009) Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway. Int J Biochem Cell Biol 41(3):467-471
14. Ball HJ, Sanchez-Perez A, Weiser S, Austin CJ, Astelbauer F, Miu J, McQuillan JA, Stocker R, Jermiin LS, Hunt NH (2007) Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene 396(1):203-213
15. Witkiewicz AK, Costantino CL, Metz R, Muller AJ, Prendergast GC, Yeo CJ, Brody JR (2009) Genotyping and expression analysis of IDO2 in human pancreatic cancer: A novel, active target. J Am Coll Surg 208(5):781-787; discussion 787-789
16. Agaugue S, Perrin-Cocon L, Coutant F, Andre P, Lotteau V (2006) 1-Methyl-tryptophan can interfere with TLR signaling in dendritic cells independently of IDO activity. J Immunol 177(4): 2061-2071
17. Yuasa HJ, Ball HJ, Austin CJ, Hunt NH (2010) 1-L-methyltryptophan is a more effective inhibitor of vertebrate IDO2 enzymes than 1-D-methyltryptophan. Comp Biochem Physiol 157(1):10-15
18. Austin CJ, Mailu BM, Maghzal GJ, Sanchez-Perez A, Rahlfs S, Zocher K, Yuasa HJ, Arthur JW, Becker K, Stocker R, Hunt NH, Ball HJ (2010) Biochemical characteristics and inhibitor selectivity of mouse indoleamine 2,3-dioxygenase-2. Amino acids 39(2):565-578
19. Lob S, Konigsrainer A, Schafer R, Rammensee HG, Opelz G, Terness P (2008) Levo-but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood 111(4):2152-2154
20. Lob S, Konigsrainer A, Rammensee HG, Opelz G, Terness P (2009) Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: Can we see the wood for the trees? Nat Rev 9(6):445-452
21. Yuasa HJ, Ball HJ, Ho YF, Austin CJ, Whittington CM, Belov K, Maghzal GJ, Jermiin LS, Hunt NH (2009) Characterization and evolution of vertebrate indoleamine 2, 3-dioxygenases IDOs from monotremes and marsupials. Comp Biochem Physiol 153(2): 137-144
22. Meininger D, Zalameda L, Liu Y, Stepan LP, Borges L, McCarter JD, Sutherland CL (2011) Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors. Biochim Biophys Acta 1814(12):1947-1954
23. Lob S, Konigsrainer A, Zieker D, Brucher BL, Rammensee HG, Opelz G, Terness P (2009) IDO1 and IDO2 are expressed in human tumors: Levo-but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother 58(1):153-157
24. Sorensen RB, Kollgaard T, Andersen RS, van den Berg JH, Svane IM, Straten P, Andersen MH (2011) Spontaneous cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2. Cancer Res 71(6):2038-2044